Vous avez cherché: alendronatom (Slovène - Anglais)

Študije z alendronatom
alendronate studies

kost, ki se tvori med zdravljenjem z alendronatom, je normalne kakovosti.
the bone formed during treatment with alendronate is of normal quality.

kost, ki se tvori med zdravljenjem z alendronatom hexal, je normalne kakovosti.
bone formed during treatment with alendronate is of normal quality.

pri bolnikih s temi boleznimi je treba med zdravljenjem z alendronatom hexal spremljati serumski kalcij in simptome hipokalcemije.
in patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during treatment with alendronate.

Študije na podganah so pokazale, da je bila distocija med porodom zaradi hipokalciemije povezana z zdravljenjem z alendronatom.
studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia.

raziskave pri podganah so pokazale, da je bila distocija med porodom zaradi hipokalcemije, povezana z zdravljenjem z alendronatom.
studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia.

raziskava uporabe zdravila preotact z alendronatom je pokazala, da lahko uporaba alendronata po jemanju preotacta še dodatno poveča kostno gostoto.
the study of preotact with alendronate showed that using alendronate after preotact can bring further increases in the bone density.

Študija uporabe zdravila preotact v kombinaciji z alendronatom je pokazala, da lahko uporaba alendronata po jemanju zdravila preotact še dodatno poveča kostno gostoto.
the study of preotact with alendronate showed that using alendronate after preotact can bring further increases in bone density.

v raziskavah kombiniranja obščitničnega hormona z alendronatom, kjer je bila mineralna gostota kosti kazalec izida, niso dokazali prednosti pred uporabo posameznih zdravil.
combining parathyroid hormone with alendronate use has not been shown to provide any advantage over either form of treatment alone, when the end point of bone mineral density was evaluated.

po izsledkih študije, opravljene pri prehodu z alendronata na denosumab, predhodno zdravljenje z alendronatom pri ženskah po menopavzi z osteoporozo ni spremenilo farmakokinetike in farmakodinamike denosumaba.
in postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of denosumab were not altered by previous alendronate therapy, based on data from a transition study (alendronate to denosumab).

v 24-mesečni študiji zdravljenja s kombinacijo z alendronatom (path) so učinke zdravila preotact na arhitekturo prav tako ovrednotili s qct.
in the 24-month alendronate combination therapy study (path), the effects of preotact on bone architecture were also evaluated using qct.

kostna gostota je bila prav tako glavno merilo v drugi študiji, v kateri so proučevali uporabo zdravila preotact v kombinaciji z alendronatom (difosfonatom) ali brez njega.
the bone density was also the main measure in another study, which looked at the use of preotact with or without alendronate (a bisphosphonate).

Če jih bolnik vzame sočasno z alendronatom, lahko hrana in pijače (vključno z mineralno vodo), dodatki kalcija, antacidi in nekatera peroralna zdravila vplivajo na njegovo absorpcijo.
if taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate.

delež bolnic, ki so se zdravile z alendronatom in so doživele enega ali več zlomov vretenc, se je v primerjavi s tistimi, ki so dobivale placebo, znižal za 48 % (alendronat 3,2 % v primerjavi s placebom 6,2 %).
there was a 48 % reduction (alendronate 3.2 % vs placebo 6.2 %) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo.